Tilmicosin

Tilmicosin

Tilmicosin is a macrolide antibiotic developed for veterinary use. It is used in veterinary medicine for the treatment of bovine respiratory disease and ovine respiratory disease, as well as for the treatment of Mycoplasma infections in poultry.

Chemistry

Tilmicosin is synthesized from tylosin by replacement of the mycinose sugar by a phosphonic acid group. The chemical structure of tilmicosin is unique among the macrolide antibiotics in having a basic nitrogen in the lactone ring, which makes the molecule a weak base.

Pharmacology

Tilmicosin is rapidly absorbed after subcutaneous injection, and is widely distributed in body tissues. It is concentrated in lung tissue and pulmonary macrophages, which makes it particularly effective against respiratory pathogens. Tilmicosin is slowly eliminated from the body, mainly in the feces but also in the urine.

Clinical use

Tilmicosin is used in veterinary medicine for the treatment of bovine respiratory disease associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni. It is also used for the treatment of ovine respiratory disease associated with Mannheimia haemolytica and Pasteurella multocida. In poultry, tilmicosin is used for the treatment of chronic respiratory disease associated with Mycoplasma gallisepticum and Mycoplasma synoviae.

Safety

Tilmicosin is toxic to humans and can cause fatal cardiac arrhythmias if accidentally injected. It is also toxic to bees and aquatic organisms.

Regulation

In the United States, tilmicosin is a prescription drug regulated by the Food and Drug Administration (FDA). In the European Union, it is regulated by the European Medicines Agency (EMA).

See also

• Macrolide
• Veterinary medicine
• Bovine respiratory disease
• Ovine respiratory disease
• Mycoplasma

‎